Table 2.

Serum visfatin concentration and visfatin mRNA in CHC patients according to sex, BMI and HOMA-IR

	Men		Women		CHC patients
	BMI < 25 kg/m2	BMI ≥ 25 kg/m2	BMI < 25 kg/m2	BMI ≥ 25 kg/m2	BMI < 25 kg/m2	BMI ≥ 25 kg/m2
Serum visfatin (ng/ml)	22.40 ±4.21	23.19 ±5.75	23.59 ±4.53	21.44 ±7.71	23.07 ±4.36	22.31 ±6.76
Liver visfatin/GAPDH	1.02 ±0.47	1.09 ±0.56	1.25 ±0.60	1.37 ±0.76	1.15 ±0.55	1.23 ±0.67
p*	NS	NS	NS	NS	NS	NS
	HOMA-IR < 2.5	HOMA-IR ≥ 2.5	HOMA-IR < 2.5	HOMA-IR ≥ 2.5	HOMA-IR < 2.5	HOMA-IR ≥ 2.5
Serum visfatin (ng/ml)	21.69 ±5.67	25.00 ±5.40	20.92 ±5.68	24.79 ±8.28	21.25 ±5.55	24.90 ±6.82
Liver visfatin/GAPDH	1.10 ±0.40	1.17 ±0.70	1.49 ±0.90	1.15 ±0.49	1.32 ±0.74	1.16 ±0.59
p*	NS	NS	NS	NS	NS	NS

^*p – both for serum visfatin and liver visfatin mRNA